JOP20220144A1 - صيغ من عقاقير متعددة القواعد لتقليل السُمية لعدة أعضاء - Google Patents

صيغ من عقاقير متعددة القواعد لتقليل السُمية لعدة أعضاء

Info

Publication number
JOP20220144A1
JOP20220144A1 JOP/2022/0144A JOP20220144A JOP20220144A1 JO P20220144 A1 JOP20220144 A1 JO P20220144A1 JO P20220144 A JOP20220144 A JO P20220144A JO P20220144 A1 JOP20220144 A1 JO P20220144A1
Authority
JO
Jordan
Prior art keywords
polybase
reduce toxicity
drug formulations
multiple organs
toxicity
Prior art date
Application number
JOP/2022/0144A
Other languages
English (en)
Inventor
Manu Chaudhary
Original Assignee
Manu Chaudhary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manu Chaudhary filed Critical Manu Chaudhary
Publication of JOP20220144A1 publication Critical patent/JOP20220144A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات وصيغ من عقاقير متعددة القواعد لتقليل السُمية لعدة أعضاء بواسطة صناعة معقد كاتيوني فوق الجزيئي دون تكوين صيغة رابطة تساهمية، دون الاقتران ودون التعديل الكيميائي للشق الجزيئي الكبير المستخدم. تعمل التركيبات والصيغ بواسطة عدة آليات بالتزامن لتقليل سُمية عقاقير المضادات الحيوية الكاتيونية.
JOP/2022/0144A 2019-12-14 2020-12-13 صيغ من عقاقير متعددة القواعد لتقليل السُمية لعدة أعضاء JOP20220144A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201911051914 2019-12-14
PCT/IN2020/051027 WO2021117065A1 (en) 2019-12-14 2020-12-13 Formulations of polybasic drugs to reduce multi-organ toxicity

Publications (1)

Publication Number Publication Date
JOP20220144A1 true JOP20220144A1 (ar) 2022-06-14

Family

ID=76329703

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0144A JOP20220144A1 (ar) 2019-12-14 2020-12-13 صيغ من عقاقير متعددة القواعد لتقليل السُمية لعدة أعضاء

Country Status (15)

Country Link
US (1) US20230104323A1 (ar)
EP (1) EP4072563A4 (ar)
JP (1) JP7683941B2 (ar)
CN (1) CN115003311B (ar)
BR (1) BR112022011800A2 (ar)
CA (1) CA3164789A1 (ar)
CO (1) CO2022009909A2 (ar)
IL (1) IL293883A (ar)
JO (1) JOP20220144A1 (ar)
MX (1) MX2022007292A (ar)
PE (1) PE20221572A1 (ar)
PH (1) PH12022551452A1 (ar)
SA (1) SA522432980B1 (ar)
WO (1) WO2021117065A1 (ar)
ZA (1) ZA202207816B (ar)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6275800A (en) 1999-07-16 2001-02-05 Mallinckrodt, Inc. Inhibition of renal uptake of molecules that are potentially damaging for the kidney
FI20010764A0 (fi) 2001-04-11 2001-04-11 Map Medical Technologies Oy Kationiset dekstraanijohdannaiset käytettäväksi munuaisten suojaamiseen
WO2003080103A1 (en) * 2002-04-25 2003-10-02 Recepticon Aps Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
CA2560522A1 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
KR20110058887A (ko) * 2008-09-18 2011-06-01 마누 차우드하리 신규한 단일 유닛 카바페넴 아미노글라이코사이드 제형
US20120058936A1 (en) * 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
JP5820378B2 (ja) 2009-09-09 2015-11-24 ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
SG11201700621XA (en) * 2014-07-25 2017-02-27 Agency Science Tech & Res Antibiotic compositions for treating bacterial infections
WO2018073449A1 (en) * 2016-10-21 2018-04-26 Algipharma As Polymyxin-alginate oligomer conjugates

Also Published As

Publication number Publication date
CN115003311B (zh) 2024-04-19
MX2022007292A (es) 2022-11-14
EP4072563A4 (en) 2024-01-24
BR112022011800A2 (pt) 2022-08-30
EP4072563A1 (en) 2022-10-19
CN115003311A (zh) 2022-09-02
CA3164789A1 (en) 2021-06-17
IL293883A (en) 2022-08-01
JP2023516848A (ja) 2023-04-21
ZA202207816B (en) 2023-03-29
JP7683941B2 (ja) 2025-05-27
WO2021117065A1 (en) 2021-06-17
PE20221572A1 (es) 2022-10-06
US20230104323A1 (en) 2023-04-06
CO2022009909A2 (es) 2022-07-19
PH12022551452A1 (en) 2023-11-13
SA522432980B1 (ar) 2024-04-03

Similar Documents

Publication Publication Date Title
SA520420033B1 (ar) مركبات صيدلية
CY1124615T1 (el) Τροποποιητες της πρωτεïνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CR20240238A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)
GEAP202416015A (en) Substituted tricyclic compounds
WO2021044208A8 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
CY1121961T1 (el) Προφαρμακο που περιεχει εναν αυτο-διασπωμενο συνδετη
EA202191244A1 (ru) Новые цитостатические конъюгаты с лигандами интегрина
CY1124970T1 (el) Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1113324T1 (el) Υποκατεστημενα αμιδικα παραγωγα ως αναστολεις πρωτεϊνικων κινασων
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
JOP20210083B1 (ar) مترافقات عقار جسم مضاد تشتمل على مشتقات إكتيناسكيدين
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
MX2022015886A (es) Derivados de amidopirimidona.
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
SA522431498B1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
BR112019007927A2 (pt) conjugados de polimixina ? oligômeros de alginato
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
BR112021011325A2 (pt) Derivados de rapamicina
MX2025007836A (es) Enlazadores, enlazadores de farmaco y conjugados de los mismos y metodos de uso de los mismos
GEAP202516674A (en) Indazole macrocycles and their use
CY1108584T1 (el) Παραγωγα 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για τη θεραπεια της στειροτητας
PH12022551810A1 (en) Protein-antiviral compound conjugates